Aerosolized amphotericin B as prophylaxis for invasive pulmonary aspergillosis: a meta-analysis.

Di Xia,Wen-Kui Sun,Ming-Ming Tan,Ming Zhang,Yuan Ding,Zhi-Cheng Liu,Xin Su,Yi Shi
DOI: https://doi.org/10.1016/j.ijid.2014.11.004
IF: 12.073
2015-01-01
International Journal of Infectious Diseases
Abstract:•Animal studies showed lower overall mortality rates among animals that underwent aerosolized amphotericin B (AMB) prophylaxis (odds ratio (OR) 0.13, 95% confidence interval (CI) 0.08–0.21).•Clinical trials showed a lower incidence of invasive pulmonary aspergillosis (IPA) among patients who underwent aerosolized AMB prophylaxis (OR 0.42, 95% CI 0.22–0.79).•The prophylactic use of aerosolized AMB is effective in reducing the mortality of immunosuppressed animals.•The prophylactic use of aerosolized AMB is associated with a lower rate of IPA among high-risk patients.
What problem does this paper attempt to address?